Eversept Partners’s Surmodics SRDX Stock Holding History

Eversept Partners’s Portfolio SRDX Stock Details SRDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-47,906	Closed	-$2.69M	–	105
2021 Q1	$2.69M	Buy	47,906 +6,607	+16%	+$330K	0.14%	59
2020 Q4	$1.8M	Buy	+41,299	New	+$1.63M	0.21%	44

Other funds holding SRDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Eversept Partners's SRDX Position: Q2 2021 in Review

Eversept Partners sold out of Surmodics (SRDX) in Q2 2021, closing a stake of 47,906 shares — an estimated $2.69M sold.

Eversept Partners first reported a position in SRDX in Q4 2020 and held it in 2 quarters. The position peaked at $2.69M in Q1 2021. 147 funds tracked by Wall St. Rank hold SRDX as of Q2 2021.

Eversept Partners reported no remaining Surmodics position as of Q2 2021 after selling out during the quarter.
Eversept Partners sold 47,906 Surmodics shares in Q2 2021, an estimated $2.69M.
Eversept Partners first reported a position in Surmodics in Q4 2020 and held it in 2 quarters.
Eversept Partners's Surmodics position peaked at $2.69M in Q1 2021.
147 funds tracked by Wall St. Rank held Surmodics as of Q2 2021.

Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.